Patents Assigned to BIOASIS TECHNOLOGIES INC.
  • P97 fusion proteins
    Patent number: 11643454
    Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
    Type: Grant
    Filed: February 10, 2019
    Date of Patent: May 9, 2023
    Assignee: BIOASIS TECHNOLOGIES, INC.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-antibody conjugates and methods of use
    Patent number: 9850472
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: December 26, 2017
    Assignee: BIOASIS TECHNOLOGIES, INC.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-ANTIBODY CONJUGATES AND METHODS OF USE
    Publication number: 20160053237
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Application
    Filed: August 27, 2015
    Publication date: February 25, 2016
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler
  • P97-ANTIBODY CONJUGATES AND METHODS OF USE
    Publication number: 20130183368
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Application
    Filed: July 5, 2012
    Publication date: July 18, 2013
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Robin Hutchison, Timothy Z. Vitalis, Reinhard Gabathuler
  • P97 FRAGMENTS WITH TRANSFER ACTIVITY
    Publication number: 20130058873
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Application
    Filed: August 3, 2012
    Publication date: March 7, 2013
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • Use of p97 As An Enzyme Delivery System For The Delivery of Therapeutic Lysosomal Enzymes
    Publication number: 20100303797
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Application
    Filed: March 23, 2010
    Publication date: December 2, 2010
    Applicant: BIOASIS TECHNOLOGIES INC.
    Inventors: Christopher M. Starr, Todd Zankel